NCT02169518 (PON1) is a clinical trial in Diabetes Mellitus, sponsored by Manchester University NHS Foundation Trust.

Who is sponsoring NCT02169518?

NCT02169518 is sponsored by Manchester University NHS Foundation Trust.

What condition does NCT02169518 study?

NCT02169518 studies Diabetes Mellitus, Bariatric Surgery Candidate.

Is NCT02169518 still recruiting?

NCT02169518 is currently recruiting now. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT02169518: PON1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Recruiting now Last updated 12 April 2023

What this trial tests

trial in Diabetes Mellitus in 600 participants. Currently enrolling.

Timeline

5 July 2012

Primary endpoint
31 January 2030

31 January 2030

Quick facts

Lead sponsor	Manchester University NHS Foundation Trust
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	600
Start date	5 July 2012
Primary completion	31 January 2030
Estimated completion	31 January 2030
Sites	1 location across United Kingdom

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Bariatric Surgery Candidate — all drugs for Bariatric Surgery Candidate →

Sponsor

Manchester University NHS Foundation Trust

Who can join

Adults 20 to 75, any sex, with Diabetes Mellitus or Bariatric Surgery Candidate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese person is a vast source of inflammation. Diabetics have abnormal glucose and cholesterol metabolism which ultimately compromise their bodies' circulatory system and nerve function. Cholesterol plays a vital role in CHD. Low-density lipoprotein (LDL) particles carry cholesterol and deposit it in blood vessel walls which become damaged as a result. When LDL particles undergo changes chemically (called oxidation) or as a result of high circulating blood glucose (called glycation), they become more harmful to the body. High-density lipoprotein (HDL) particles have a protective function in CHD. Not only do they transport cholesterol away from the blood vessels to the liver to be broken down, they have properties against oxidation and inflammation. These properties are related to the activity of an enzyme on HDL called paraoxonase 1(PON1). Super-obese patients are increasingly treated by weight-reducing surgery (bariatric surgery). In this study we examine whether weight loss following bariatric surgery results in reduced inflammatory state, improved HDL function (higher PON1 activity), better control of blood glucose and less nerve damage. We will study PON1 activity, inflammation and glucose control in patients with type 1 diabetes (with and without kidney damage) and type 2 diabetes. We will also study the effects of rapidly rising blood glucose levels on PON1 and glycated LDL in patients undergoing oral glucose tolerance test.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes.
Yadav R, Hama S, Liu Y, Siahmansur T, et al · · 2017 · cited 45× · PMID 29187850 · DOI 10.3389/fimmu.2017.01512

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Manchester University NHS Foundation Trust trials

Trials by the same sponsor.

NCT07057284 — DENTOFACIAL-PBT Stage 2 - Feasibility Study · enrolling by invitation
NCT06972238 — Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia · not yet recruiting
NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting
NCT07049263 — Disparities In Access to the Northwest Ambulance Service During Pregnancy, Birth and Postpartum Period and Its Associati · active not recruiting
NCT06561334 — Spasmodic Dysphonia Interviews · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02169518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Manchester University NHS Foundation Trust
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02169518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing